Microparticles and thrombotic disease

Current Opinion in Hematology

Volumn 16, Issue 5, 2009, Pages 334-341

  Davizon, Pavel ^a   López, José A ^a,b  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer; Microparticles; Thrombosis; Tissue factor

Indexed keywords

COMPLEMENT; GROWTH ARREST SPECIFIC PROTEIN 6; LACTADHERIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PROTEIN S; SPHINGOLIPID; THROMBOPLASTIN;

CANCER PATIENT; CELL ISOLATION; FLOW CYTOMETRY; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; LIGHT SCATTERING; PARTIAL THROMBOPLASTIN TIME; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; THROMBOSIS;

CELL-DERIVED MICROPARTICLES; HEMOSTASIS; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 69549116335     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32832ea49c     Document Type: Review

References (86)

1. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005; 20:22-27. (Pubitemid 40363367)
2. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101:439-451.
3. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004; 16:415-421. (Pubitemid 38903148)
4. Chargaff E, West R. The biological significance of the thromboplastic protein of blood. J Biol Chem 1946; 166:189-197.
5. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13:269-288.
6. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106:1604-1611. (Pubitemid 41208572)
7. Bebawy M, Combes V, Lee E, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009 [Epub ahead of print]. Another example of intercellular delivery of proteins exerted by microparticles.
8. Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100:878-885. Interesting in-vitro data showing the effect of the interaction between microparticles and endothelial cells.
9. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008; 3:e3694. This is one of the first reports showing microRNA associated with microvesicles.
10. Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110:2440-2448. (Pubitemid 47523165)
11. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10:619-624. Through very elegant experiments, authors show the intercellular courier role played by microparticles. (Pubitemid 351627382)
12. Habib A, Kunzelmann C, Shamseddeen W, et al. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 2008; 93:941-942. High levels of microparticles are clearly shown in this group of patients. (Pubitemid 351821736)
13. Yu J, May L, Milsom C, et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008; 28:1975-1981. The proangiogenic role exerted by TF through the activation of coagulation and the intercellular transfer by TF-bearing microparticles is elegantly shown.
14. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197:1585-1598. (Pubitemid 36682554)
15. Shurin MR, Potapovich AI, Tyurina YY, et al. Recognition of live phosphatidylserine- labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer. Cancer Res 2009; 69:2487-2496.
16. Freikman I, Amer J, Cohen JS, et al. Oxidative stress causes membrane phospholipid rearrangement and shedding from RBC membranes: an NMR study. Biochim Biophys Acta 2008; 1778:2388-2394.
17. Simak J, Holada K, Risitano AM, et al. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2004; 125:804-813. (Pubitemid 38813608)
18. Diehl P, Nagy F, Sossong V, et al. Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost 2008; 99:711-719. (Pubitemid 351694227)
19. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32:11-23.
20. Bidot L, Jy W, Bidot C Jr, et al. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost 2008; 6:913-919. Interesting observations around the existing prothrombotic burden in patients with recurrent thrombosis, the participation of microparticles, and the potential use of this thrombin generation assay to assess it. (Pubitemid 351689911)
21. Wolfs JL, Comfurius P, Bekers O, et al. Direct inhibition of phospholipid scrambling activity in erythrocytes by potassium ions. Cell Mol Life Sci 2009; 66:314-323.
22. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspaseindependent manner to promote apoptosis-like events during platelet activation. Blood 1999; 94:1683-1692.
23. Biro E, Akkerman JW, Hoek FJ, et al. The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost 2005; 3:2754-2763. (Pubitemid 41819805)
24. Pendurthi UR, Rao LV. Role of tissue factor disulfides and lipid rafts in signaling. Thromb Res 2008; 122 (Suppl 1):S14-S18. Insightful review about tissue factor.
25. Jy W, Horstman LL, Jimenez JJ, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2:1842-1851.
26. Toth B, Liebhardt S, Steinig K, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008; 100:663-669. The potential use of microparticles as biomarkers is presented, particularly in cancer patients.
27. Cantin R, Diou J, Belanger D, et al. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods 2008; 338:21-30.
28. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6:1517-1524. The burden exerted by tumor-derived TF-bearing microparticles is elegantly shown in mice.
29. Morel N, Morel O, Petit L, et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. J Trauma 2008; 64:698-704.
30. Lawrie AS, Albanyan A, Cardigan RA, et al. Microparticle sizing by dynamic light scattering in fresh-frozen plasma. Vox Sang 2009 [Epub ahead of print].
31. Dasgupta SK, Abdel-Monem H, Niravath P, et al. Lactadherin and clearance of platelet-derived microvesicles. Blood 2009; 113:1332-1339. Interesting role of phosphatidylserine binding proteins in the clearance of microparticles.
32. Stuart LM, Ezekowitz RA. Phagocytosis: elegant complexity. Immunity 2005; 22:539-550.
33. Hanayama R, Tanaka M, Miwa K, et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002; 417:182-187. (Pubitemid 34506799)
34. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006; 36:182-187.
35. Sadallah S, Eken C, Schifferli JA. Erythrocyte-derived ectosomes have immunosuppressive properties. J Leukoc Biol 2008; 84:1316-1325. Interesting in-vitro studies pointing toward possible deleterious effects of microparticles.
36. Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008; 122:599-603. This study analyzes the prothrombotic burden exerted by an increase in circulating microparticles due to a delayed clearance mechanism.
37. Shah MD, Bergeron AL, Dong JF, Lopez JA. Flow cytometric measurement of microparticles: pitfalls and protocol modifications. Platelets 2008; 19:365-372. A good analysis of the variables hindering the study of microparticles.
38. Berckmans RJ, Neiuwland R, Boing AN, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85:639-646.
39. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97:425-434.
40. Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87:1409-1415. (Pubitemid 26056904)
41. Castaman G, Yu-Feng L, Battistin E, Rodeghiero F. Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation. Br J Haematol 1997; 96:458-463. (Pubitemid 27087227)
42. Joop K, Berckmans RJ, Nieuwland R, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85:810-820. (Pubitemid 32421813)
43. Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109:1931-1937. (Pubitemid 46348189)
44. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113:1112-1121. Very interesting data showing the contribution of megakaryocyte-derived microparticles to the basal level found in blood, as well as the differences between the platelet and megakaryocyte derived microparticles.
45. Del Conde I, Cruz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201:871-879. (Pubitemid 40524457)
46. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19:225-233. (Pubitemid 351574446)
47. Leroyer AS, Tedgui A, Boulanger CM. Microparticles and type 2 diabetes. Diabetes Metab 2008; 34 (Suppl 1):S27-S32.
48. Ueba T, Haze T, Sugiyama M, et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008; 100:280-285.
49. Messer L, Alsaleh G, Freyssinet JM, et al. Microparticle-induced release of B-lymphocyte regulators by rheumatoid synoviocytes. Arthritis Res Ther 2009; 11:R40.
50. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25:287-294.
51. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938-949. The contribution of TF and TF-bearing microparticles to thrombus formation is detailed.
52. Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008; 111:1208-1216. (Pubitemid 351213402)
53. Panes O, Matus V, Saez CG, et al. Human platelets synthesize and express functional tissue factor. Blood 2007; 109:5242-5250. (Pubitemid 46890544)
54. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86:214-221. (Pubitemid 32666187)
55. Reinhardt C, von Bruhl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118:1110-1122. This paper shows the role of disulfide isomerization in the decryption of TF.
56. Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke 2008; 39:1269-1275.
57. Ferro D, Basili S, Alessandri C, et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149:111-116. (Pubitemid 30125978)
58. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17:265-272.
59. Dietzen DJ, Page KL, Tetzloff TA, et al. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol 2007; 27:690-696.
60. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1861.
61. Pluskota E, Woody NM, Szpak D, et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood 2008; 112:2327-2335. A very interesting article that shows platelet activation through Mac-1 exposed on neutrophil-derived microparticles. Another mechanism toward thrombus formation.
62. Pattanapanyasat K, Noulsri E, Fucharoen S, et al. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry B Clin Cytom 2004; 57:23-31. (Pubitemid 38297620)
63. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137:398-407.
64. Olmos L, Mombouli JV, Wasserstrum N, Vanhoutte PM. Ability of sickle cells to scavenge endothelium-derived nitric oxide is reduced. Acta Pharmacol Sin 2002; 23:967-973. (Pubitemid 35285177)
65. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 2008; 44:1506-1528.
66. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102:2678-2683. (Pubitemid 37193612)
67. José A, López, Del Conde I. Platelets and coagulation. In: Gresele P, Fuster V, Lopez JA, Page CP, Vermylen J, editors. Platelets in hematologic and cardiovascular disorders. Cambridge, UK: Cambridge University Press; 2008. p. 80.
68. Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 2005; 62:S4-S6. (Pubitemid 41705175)
69. Lee AY. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematol Am Soc Hematol Educ Program 2006:438-443.
70. Del Conde I, Bharwani LD, Dietzen DJ, et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5: 70-74. (Pubitemid 44921069)
71. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110:1723-1729. (Pubitemid 47443881)
72. Donati MB. Thrombosis and cancer: Trousseau syndrome revisited. Best Pract Res Clin Haematol 2009; 22:3-8.
73. Carr JM, Dvorak AM, Dvorak HF. Circulating membrane vesicles in leukemic blood. Cancer Res 1985; 45:5944-5951.
74. Dvorak HF, Quay SC, Orenstein NS, et al. Tumor shedding and coagulation. Science 1981; 212:923-924.
75. Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112:853-862. (Pubitemid 38063743)
76. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34:195-198.
77. Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13:362-367. (Pubitemid 47472294)
78. Tesselaar ME, Romijn FP, Van DL, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5:520-527.
79. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, et al. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:1456-1462. (Pubitemid 46809438)
80. Singhal AK, Orntoft TF, Nudelman E, et al. Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res 1990; 50:1375-1380. (Pubitemid 20090443)
81. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr Opin Hematol 2008; 15:522-528.
82. Toth B, Nieuwland R, Liebhardt S, et al. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 2008; 28:1107-1112. (Pubitemid 351578961)
83. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111:25-27.
84. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 2001; 98:7742-7747. (Pubitemid 32642631)
85. Zania P, Kritikou S, Flordellis CS, et al. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006; 318:246-254. (Pubitemid 43920762)
86. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101:877-889. (Pubitemid 28096085)